Eric Bjerkholt, M.B.A.
DirectoratMirum Pharmaceuticals· In proxies 2022–2025
Pay in FY2025+62% from the year before · Mirum Pharmaceuticals stock +91.0% the same year
Eric Bjerkholt, M.B.A. was paid $3.2M in FY2025 (Dec), up 62%. Mirum Pharmaceuticals stock rose 91.0% that year.
Pay$100 in the stock at the end of FY21 → $495
Experience
- Metagenomi TherapeuticsPublic company · 2 yr
- Director2024 – Present · 2 yrNo stock prices for these years
- CerusPublic company · 3 yr
- Director2023 – Present · 3 yrNo stock prices for these years
- Surrozen, Inc./DEPublic company · 3 yr
- Director2023 – Present · 3 yrNo stock prices for these years
- Mirum PharmaceuticalsPublic company · 4 yr
- Chief Financial Officer2022 – Present · 4 yrStock in role +447%
- Metagenomi Therapeutics, Inc.Public company · 1 yr
- Director2025 – Present · 1 yrNo stock prices for these years
- Metagenomi, Inc.Public company
- Director? – PresentNo stock prices for these years
- Surrozen, Inc.Public company · 3 yr
- Director2023 – Present · 3 yrNo stock prices for these years
- Graybug Vision, Inc.Public company · 5 yr
- Director2020 – 2025 · 5 yrNo stock prices for these years
- CalciMedica, Inc.Public company · 5 yr
- Director2020 – 2025 · 5 yrNo stock prices for these years
Roles come from the proxy statements of each company.
Boards3
- CerusDirector · 7 yr on the boardIndependentAudit (Chair)—Paid as an executive
- Surrozen, Inc./DEDirector · 2 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Metagenomi TherapeuticsDirector · 0 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
Board seats come from each company's latest proxy statement.
Activity
Two people shown as one, or a wrong number?